Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 151

1.

Oncolytic viruses for induction of anti-tumor immunity.

Tong AW, Senzer N, Cerullo V, Templeton NS, Hemminki A, Nemunaitis J.

Curr Pharm Biotechnol. 2012 Jul;13(9):1750-60. Review.

PMID:
21740355
[PubMed - indexed for MEDLINE]
2.

Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.

Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF, Springfeld C, Jaeger D, von Kalle C, Ungerechts G.

Hum Gene Ther. 2013 Jul;24(7):644-54. doi: 10.1089/hum.2012.205.

PMID:
23642239
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Multiscale model for the effects of adaptive immunity suppression on the viral therapy of cancer.

Paiva LR, Silva HS, Ferreira SC, Martins ML.

Phys Biol. 2013 Apr;10(2):025005. doi: 10.1088/1478-3975/10/2/025005. Epub 2013 Mar 15.

PMID:
23492870
[PubMed - indexed for MEDLINE]
4.

Combining oncolytic virotherapy and tumour vaccination.

Bridle BW, Hanson S, Lichty BD.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):143-8. doi: 10.1016/j.cytogfr.2010.02.009. Epub 2010 Mar 11. Review.

PMID:
20226716
[PubMed - indexed for MEDLINE]
5.

Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.

Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, Nokisalmi P, Dotti G, Guse K, Laasonen L, Partanen K, Karli E, Haavisto E, Oksanen M, Karioja-Kallio A, Hannuksela P, Holm SL, Kauppinen S, Joensuu T, Kanerva A, Hemminki A.

Int J Cancer. 2012 Apr 15;130(8):1937-47. doi: 10.1002/ijc.26216. Epub 2011 Aug 8.

PMID:
21630267
[PubMed - indexed for MEDLINE]
6.

Impact of tumor microenvironment on oncolytic viral therapy.

Wojton J, Kaur B.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):127-34. doi: 10.1016/j.cytogfr.2010.02.014. Review.

PMID:
20399700
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Evolution of oncolytic viruses: novel strategies for cancer treatment.

Atherton MJ, Lichty BD.

Immunotherapy. 2013 Nov;5(11):1191-206. doi: 10.2217/imt.13.123. Review. Erratum in: Immunotherapy. 2014 May;6(5):657-8.

PMID:
24188674
[PubMed - indexed for MEDLINE]
8.

Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?

Naik JD, Twelves CJ, Selby PJ, Vile RG, Chester JD.

Clin Cancer Res. 2011 Jul 1;17(13):4214-24. doi: 10.1158/1078-0432.CCR-10-2848. Epub 2011 May 16.

PMID:
21576084
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, Vile RG.

Hum Gene Ther. 2009 Oct;20(10):1119-32. doi: 10.1089/hum.2009.135. Review.

PMID:
19630549
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.

Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, Nokisalmi P, Raki M, Laasonen L, Särkioja M, Rajecki M, Kangasniemi L, Guse K, Helminen A, Ahtiainen L, Ristimäki A, Räisänen-Sokolowski A, Haavisto E, Oksanen M, Karli E, Karioja-Kallio A, Holm SL, Kouri M, Joensuu T, Kanerva A, Hemminki A.

Cancer Res. 2010 Jun 1;70(11):4297-309. doi: 10.1158/0008-5472.CAN-09-3567. Epub 2010 May 18.

PMID:
20484030
[PubMed - indexed for MEDLINE]
Free Article
11.

Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.

Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, Tähtinen S, Oksanen M, Heiskanen R, Pesonen S, Joensuu T, Alanko T, Partanen K, Laasonen L, Kairemo K, Pesonen S, Kangasniemi L, Hemminki A.

Clin Cancer Res. 2013 May 15;19(10):2734-44. doi: 10.1158/1078-0432.CCR-12-2546. Epub 2013 Mar 14.

PMID:
23493351
[PubMed - indexed for MEDLINE]
Free Article
12.

Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.

Sinkovics JG, Horvath JC.

Arch Immunol Ther Exp (Warsz). 2008 Dec;56 Suppl 1:3s-59s. doi: 10.1007/s00005-008-0047-9. Epub 2008 Dec 23. Review.

PMID:
19104757
[PubMed - indexed for MEDLINE]
13.

Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.

Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, Bramante S, Parviainen S, Kanerva A, Loskog AS, Eliopoulos AG, Pesonen S, Hemminki A.

Cancer Res. 2012 May 1;72(9):2327-38. doi: 10.1158/0008-5472.CAN-11-2975. Epub 2012 Mar 6.

PMID:
22396493
[PubMed - indexed for MEDLINE]
Free Article
14.

Evaluation of innate immune signaling pathways in transformed cells.

Heiber JF, Barber GN.

Methods Mol Biol. 2012;797:217-38. doi: 10.1007/978-1-61779-340-0_15. Review.

PMID:
21948479
[PubMed - indexed for MEDLINE]
15.

Oncolytic viruses from the perspective of the immune system.

Alemany R, Cascallo M.

Future Microbiol. 2009 Jun;4(5):527-36. doi: 10.2217/fmb.09.28.

PMID:
19492964
[PubMed - indexed for MEDLINE]
16.

Oncolytic herpes virus induces effective anti-cancer immunity against murine colon cancer.

Shirota T, Kasuya H, Kodera Y, Nishikawa Y, Shikano T, Sahin TT, Gewen T, Yamamura K, Fukuda S, Kanzaki A, Yamada S, Fujii T, Sugimoto H, Nomoto S, Takeda S, Nakao A.

Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1482-9. doi: 10.5754/hge11168. Epub 2011 Jul 15.

PMID:
21940320
[PubMed - indexed for MEDLINE]
17.

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, Medley LC, Michael A, Nutting CM, Pandha HS, Shorrock CA, Simpson J, Steiner J, Steven NM, Wright D, Coombes RC.

Clin Cancer Res. 2006 Nov 15;12(22):6737-47.

PMID:
17121894
[PubMed - indexed for MEDLINE]
Free Article
18.

Fusogenic oncolytic herpes simplex viruses as a potent and personalized cancer vaccine.

Li QX, Liu G, Zhang X.

Curr Pharm Biotechnol. 2012 Jul;13(9):1773-85. Review.

PMID:
21740353
[PubMed - indexed for MEDLINE]
19.

Oncolytic HSV as a vector in cancer immunotherapy.

Li H, Zhang X.

Methods Mol Biol. 2010;651:279-90. doi: 10.1007/978-1-60761-786-0_16.

PMID:
20686972
[PubMed - indexed for MEDLINE]
20.

Oncolytic herpes simplex virus type 1 and host immune responses.

Fukuhara H, Todo T.

Curr Cancer Drug Targets. 2007 Mar;7(2):149-55. Review.

PMID:
17346106
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk